Friday, October 2, 2015

Valeant’s High-Price Drug Strategy by GRETCHEN MORGENSON


By GRETCHEN MORGENSON

Valeant, which has grown by acquiring rivals and slashing their staffs, has raised the ire of a House panel, which is now considering a subpoena on the company’s price increases.

Published: October 4, 2015 at 12:00AM

from NYT Business Day http://ift.tt/1P9dDHo



from WordPress http://ift.tt/1Lo6Jhy
via Hadi Aboukhater

No comments:

Post a Comment